The FDA approval of Patanase nasal spray was based primarily on multiple clinical studies for the evaluation of safety, efficacy and onset of action. The results of these clinical studies were that patients treated with Patanase, two sprays per nostril, twice daily, demonstrated significantly greater decreases in total nasal symptom scores (TNSS) compared to the placebo nasal spray.
Patanase nasal spray, an extension to the company’s market-leading ocular allergy product line, will be available in May, 2008.
Kevin Buehler, Alcon’s senior vice president, global markets and chief marketing officer, said: “We look forward to providing doctors the opportunity to prescribe Patanase to their patients who need and want a fast-acting nasal spray that quickly relieves symptoms.”